Outcomes of sensitivity analysis
| Combinations | Effectiveness (E) % | C′ | C′/E | ΔC′/ΔE |
| CEA+CA125 | 75.85 | 78.3 | 1.032301 | 0 |
| CEA+CA211 | 77.03 | 118.8 | 1.542329 | 34.42736 |
| CA50+CA211 | 75.20 | 139.5 | 1.855049 | −94.1767 |
| CEA+CA50+CA125 | 84.08 | 127.8 | 1.519992 | 6.015012 |
| CEA+CA50+CA211 | 88.27 | 168.3 | 1.906657 | 7.246567 |
| CEA+CA125+CA211 | 84.86 | 168.3 | 1.983365 | 9.993564 |
| CA50+CA125+CA211 | 83.65 | 189 | 2.259362 | 14.18877 |
| CEA+CA50+CA125+CA211 | 92.27 | 217.8 | 2.360531 | 8.497098 |
| CEA+NSE+SCC | 76.82 | 176.4 | 2.296412 | 101.6071 |
| CEA+NSE+CA211 | 84.08 | 176.4 | 2.09802 | 11.92084 |
| CEA+SCC+CA211 | 83.75 | 208.8 | 2.493112 | 16.51739 |
| NSE+SCC+CA211 | 76.19 | 237.6 | 3.118397 | 464.4556 |
| CEA+NSE+SCC+CA211 | 88.74 | 266.4 | 3.002053 | 14.59352 |
CA50, cancer antigen-50; CEA, carcinoembryonic antigen; NSE, neuron-specific enolase; SCC, squamous cell carcinoma antigen.